Answers are grounded in this paper and cite their sources.
OBJECTIVE: Aim: To study biochemical changes in women with breast cancer according to treatment protocols, with emphasis on liver and metabolic markers. PATIENTS AND METHODS: Materials and Methods: A descriptive comparative cross-sectional study of 141 women including chemotherapy only (n=50), newly diagnosed n=46 and chemotherapy + metformin n=45 was conducted. The glucose, albumin, ALP, AST, ALT, creatinine and total bilirubin were determined in venous samples of blood by standard enzymatic methods. Data were presented as mean±SD and analyzed with one-way ANOVA. RESULTS: Results: Glucose and ALP levels were significantly different. Compared with chemotherapy-only (86.38±15.96 mg/dL) and newly diagnosed groups, increased glucose (197.15±58.15 mg/dL) in the chemotherapy + metformin group p<0.001. Higher ALP was also noted in the metformin group (127.35±58.88 U/L) compared with chemotherapy alone (105.02±30.96 U/L) and newly diagnosed patients (108.81±40.84 U/L), p=0.039. Albumin, AST, ALT, creatinine and total bilirubin were not statistically different. AST was moderately correlated with ALT (r=0.524) and strongly correlated with total bilirubin r=0.752, p<0.001. CONCLUSION: Conclusions: The consumption of breast cancer therapy caused metabolic changes especially on glucose and ALP. Normal biochemical markers are still useful in surveillance for metabolic derangements due to treatment.
No takes yet. Share an insight, caveat, or question.
Amshawee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: